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Abstract
Background: Anemic syndrome is a frequent problem in intensive care units. The most probable
etiology is the suppression of the erythropoietin response due to the direct effects of cytokines, as
well as frequent blood sampling.
Transfusions are not free of complications, therefore transfusion reactions are estimated to occur
in 2% of the total packed red blood cells (pRBCs) transfused.
In the past several years, several trials had tried to compare the restrictive with the more liberal
use of transfusions, and they were found to be equally effective.
Nosocomial pneumonia is the most common nosocomial infection in intensive care units; the
prevalence is 47% with an attributive mortality of 33%.
There are multiple risk factors for the development of nosocomial pneumonia. Colonization of the
upper airways is the most important pathophysiological factor but there are other factors
implicated like, sedation techniques, inappropriate use of antibiotics and recumbent positioning.
A secondary analysis of the CRIT study describes transfusion therapy and its practices in the United
States. They found that transfusion practice is an independent risk factor for the development of
nosocomial pneumonia.
Methods: This is a multicenter, prospective cohort study in different intensive care units in
Colombia. A total of 474 patients were selected who had more than 48 hours of mechanical
ventilation.
The primary objective is to try to demonstrate the hypothetical relationship between the use of
transfusions and nosocomial pneumonia.
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pneumonia in intensive care units and describe the incidence of pneumonia and transfusion
practices.
Discussion: Ventilator associated pneumonia is a primary problem in the intensive care unit,
multiple factors have been associated with its presence in this study we try to explore the possible
association between pneumonia and transfusion, describe all other factors associated with this, and
the possible association with other nosocomial infections.
Background
Anemia is a frequent problem in intensive care units. The
most probable etiology is the suppression of the erythro-
poietin response due to the direct effects of cytokines, as
well as frequent blood sampling [1].
In the United States it is estimated that 3,500 transfusions
are given daily, around 1.25 million transfusions through-
out the year, and 73% of patients that stay in an intensive
care unit for more than 7 days are transfused [2], with pre-
transfusion average hemoglobin of 8.4 g/dL
One of the most alarming risks of anemia is lost of capac-
ity to transport oxygen. Nevertheless, animal studies have
found tolerance levels of hemoglobin as low as 3 g/dL, as
well as a good tolerance of hemodilution, electrocardio-
graphic changes and ventricular function, at these levels
[3,4].
Elderly patients with coronary artery disease, cerebrovas-
cular disease and pulmonary disease are groups consid-
ered intolerant to important decreases in the levels of
hemoglobin. A common use of transfusion practice in
hospitalized patients is to maintain hemoglobin levels
within normal limits. However, there is no evidence that
confirms these findings [5].
Transfusion practice involves multiple health risk due to
its inadequate use. Adverse effects are frequent and can
present in up to 2% of transfusions including infrequent
diseases as hepatitis C and HIV [6] as well as immune-
mediated reactions, with an incidence of 1 in 1.000.000
fatal hemolytic reactions [7]. Other more commonly seen
are fluid overload along with noninfectious complica-
tions such as non- hemolytic, febrile reactions as well as
allergic reactions.
TRALI is a non-cardiogenic type of pulmonary edema
associated with transfusions, classified as a serious com-
plication, which has been the cause of 45 deaths within
1992 – 2002. Its pathogenesis is the entrapping of leuko-
cytes in the pulmonary microcirculation with an increase
in pulmonary permeability [8]. Immunomodulation-
associated transfusion which was used in the past to
improve survival in transplanted patients has not been
systematically studied. An association between the recur-
rence of cancer, the presence of nosocomial infections and
the use of transfusions has been reported [9]. There is evi-
dence that stored leukocytes found in a unit of blood
could produce cytokines that interfere with the immune
function. A transfusion introduces new antigens as Histo-
compatibility antigens (HLA) which interact with native
T-cells as well as molecules called co stimulators that can
cause a suppression of immune response [10].
Microquimerism has been proposed as another mecha-
nism of immunomodulation-associated transfusions.
Although, HLA compatibility between donor and receiver
can result in the persistence of leukocytes from the donor
and antigen presenting cells causing a decrease immune
response and a tolerance to the antigens from the donor.
Microquimerism results in the release of IL – 4, IL – 10
and transforming growth β factor; cytokines that inhibit
the production of other inflammatory molecules. The loss
of immunogenicity by transfused leukocytes results in
anergy from T cells as well as immunosupression [11].
Different studies have reported the association between
transfusions and nosocomial infection [9,12,13]. The
immunomodulation generated by transfusions is a factor
associated with the presence of intrahospital infections
which has a great impact on mortality and costs generated
from intensive care units.
Ventilator associated pneumonia (VAP) is the most com-
mon infection found in intensive care units (ICU's), with
a prevalence of 47% of total infections in ICU[14]; 25% of
all nosocomial infections, with an estimated 5 to 10 VAP
cases per 1000 hospital admissions and 9 – 27% of intu-
bated patients with an attributable mortality of 33%
[15,16]. In addition, VAP contributes to increase morbid-
ity due to length of stay on mechanical ventilation and
hospital stay [16,17], and increasing hospital costs
[18,19]. In the United States, VAP can cost approximately
40,000 dollars per case, presenting 300,000 new cases
annually. Therefore, the amounts of resources used for
treatment are huge; placing efforts to prevent this pathol-
ogy. The main risk factor for VAP is the length of stay on
mechanical ventilation increasing colonization of upper
airways and stomach by pathogenic germs, further predis-Page 2 of 5
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physiology for VAP [20]. Stomach colonization by
pathogenic germs as a source of pneumonia is related to
multiple factors such as an inadequate use of antibiotics,
prophylaxis use for stress ulcers, supine position, severity
of disease including hemodinamic instability and use of
vasopressors; the use of continuous sedation as well as
parenteral nutrition. Recognizing the risk factors might
enable us to establish suitable measures for the preven-
tion and management of VAP.
44% of the patients received one or more units of packed
red blood cells during their stay in the ICU [21], these
transfusions have been associated with the disruption of
the immune response in the receptor [22,23] and related
to the presence of severe nosocomial infections other than
VAP [9,24-26]. Recently, one analysis of transfusion prac-
tice in the United States found an association between the
transfusion and VAP [13]. However, no studies have been
done to try and find an association between transfusions
and VAP as a primary endpoint. Different trials that have
found an association between nosocomial infection and
transfusions were retrospective and other results came
from secondary analysis or from transfusion practices. At
this moment, evidence support that conservative transfu-
sion practice in critically ill patients is as effective as the
liberal strategies in terms of morbidity and mortality [27].
Unfortunately, we do not know if these practices are pres-
ently done in our ICU's. As previously stated, we consider
that this study is very important and necessary to answer
if there is truly a correlation between VAP and use of trans-
fusions as well as to know the transfusion practices in our
institutions. With this present study, we want to confirm
the association between red blood cell transfusions and
VAP as a primary endpoint. Also, identify the incidence of
VAP in our ICU's establishing its characteristics, total mor-
tality, mortality attributed to VAP and length of ICU stay
as a secondary endpoint. Our theory is that if an associa-
tion is found, then it is possible that by decreasing the fre-
quency of transfusions this will decrease the incidence of




1. Establish the association between transfusion of packed
red blood cells (pRBCs) and Ventilator associated pneu-
monia (VAP).
Secondary objective
1. Describe the demographic variables in both groups.
2. Establish the incidence of VAP in both groups.
3. Establish current transfusion practices in ICU.
4. Establish the main risk factors associated with the onset
of VAP in our population.
5. Estimate the incidence of anemia in patients on
mechanical ventilation.




Patients on mechanical ventilation who are transfused
with packed red blood cells present an incidence of NAV




This is a prospective, multicenter, cohort study.
In the design of the study the comparison between both
groups was made with a proportion of 1:1, the disparity
reason of presenting VAP in patients with mechanical ven-
tilation who were transfused is 1.89 [13] and the preva-
lence of VAP in the ICU is an average of 18% [16]. The
sample size calculated based on the reason of disparity of
the exposed group and the prevalence of the disease in the
group not exposed, with an error alpha of a 0,05 and
power of 0.8, the number of people that is required is of
237 patients in each arm (total of 474) to two tails. To cal-
culate the sample we are going to use the program Epi-
Info for cohort studies [28].
Inclusion criteria
Patients with mechanical ventilation for more than 48
hours
Exclusion criteria
-Younger than 18 years old.
-Pregnancy.
-Patients with contraindications for transfusion of packed
red blood cells.
-Patients involved in other related investigations of trans-
fusion practices.
-Patients with diagnosis of pneumonia within the first 48
hours of admission to ICU. (Community acquired pneu-
monia or nosocomial pneumonia).
Techniques and procedures
The study will appear to the committee of ethics and
investigation of the Instituto de Ciencias of Salud (CES),Page 3 of 5
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requires it. Then we will present to the National Network
of Investigation in Mechanical Ventilation that includes
ICU of Medellín, Bogota, Cali and Barranquilla.
Once the inclusion criteria are fulfilled, the patients will
be followed up for 30 days, hospital discharge or death
according to the first occurrence.
All the doctors will be informed about the characteristics
of the study, admission criteria, measures of support and
the clinical handling of the patients during their ICU stay.
Statistical analysis
The continuous variables will be expressed as average with
their standard deviation and the t Student will be used for
the comparison between the averages in both groups. The
categorical variables will be expressed as frequency alloca-
tions and the test of the chi-square will be used to deter-
mine the differences between the frequency allocations in
both groups. A univariate analysis will be used and a mul-
tivariate logistic regression analysis to fit the independent
risk factors for the development of VAP.
The respective relative risks with their corresponding con-
fidence interval (CI) of 95% will be reported. A p value of
<0.05 will be considered to determine the statistical sig-
nificance. The analysis will take control of the statistical
program SPSS 13. (Chicago).
Ethical aspects
The investigation will carry out previous academic and
ethical endorsements from CES and other research com-
mittees of each of the participating Clinics and Hospitals
in the project. In this study the scientific norms, technical
and administrative are fulfilled for the investigation in
health emanated by the Ministry of Health of Colombia
(resolution 8430 of 1993, by which the norms scientific,
technical, and administrative settle down for the investi-
gation in health). The investigation is based on solid sci-
entific knowledge and it is executed by suitable medical
personnel with experience in the handling of patients
with this pathology.
Discussion
The patients in the intensive care frequently are coming
anemic, the etiology of this is the poor availability of iron
and medullar depression by cytoquines [1], however the
real impact of maintaining a good level of hematocrit in
the intensive care patients is questionable, Hebert and
colls in a previous trials demonstrated that a conservative
management of transfusions is equal effective than a more
liberal management [5].
The immunosuppressant effects of transfusion is not
really studied, there are many studies that tried to made a
relation between transfusion and infectious complica-
tions as a consequence of the immunosuppressant effects,
Andrew Shorr and Colls as a results of a secondary analy-
sis of the Crit study demonstrated a possible relation
between ventilator associated pneumonia and transfu-
sions[13].
Ventilator associated pneumonia constitute a primary
problem in the actual management of patients in inten-
sive care units, associated with important morbidity and
attributable mortality[15,16] multiple risk factors had
been associated with its presence[16].
We design a multi center prospective cohort study in mul-
tiple intensive care units in Colombia, we will follow for
thirty days, patients in mechanical ventilation who do not
have initial diagnosis of pneumonia.
We will describe all variables associated with pneumonia
and transfusions and then after an unvaried analysis and
a logistic regression analysis we will establish a really asso-
ciation between transfusion and pneumonia and all other
factors associated with this.
Several risk factors have been associated with the occur-
rence of ventilator associated pneumonia, we will estab-
lish the really presence of this factors and the possible
association between transfusion and ventilator associated
pneumonia, also we will describe the transfusion policies
in our intensive care units and the possible relation with
other nosocomial infections.
Conclusion
This is a multi center cohort study in various intensive care
unit in Colombia, we will try to demonstrated as a first
end point the association between pneumonia and trans-
fusion, and all other risk factors associated with this, also
we will establish the incidence of ventilator associated
pneumonia and the main epidemiological factors, estab-
lish the incidence of anemia in mechanical ventilated
patients and the current transfusion practice in our media.
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